N'-[1-cyclopropyl-methylidene]-hydrazinecarboxylic acid tert-butyl ester | 1187368-92-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N'-[1-cyclopropyl-methylidene]-hydrazinecarboxylic acid tert-butyl ester
• 英文别名: 2-(Cyclopropylmethylene)hydrazinecarboxylic acid 1,1-dimethylethyl ester；tert-butyl N-(cyclopropylmethylideneamino)carbamate
• CAS: 1187368-92-8
• 化学式: C₉H₁₆N₂O₂
• 分子量: 184.238
• InChiKey: CQGJBDJDWZLPGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N'-[1-cyclopropyl-methylidene]-hydrazinecarboxylic acid tert-butyl ester 在 sodium cyanoborohydride 、 溶剂黄146 、 sodium hydroxide 作用下， 以 水 、 溶剂黄146 为溶剂， 生成 tert-butyl 2-(cyclopropylmethyl)hydrazine-1-carboxylate
  参考文献：
  名称：

  [EN] THIAZOLYL-DIHYDRO-INDAZOLES
  [FR] THIAZOLYLDIHYDROINDAZOLES

  摘要：

  本发明涵盖了一般式（1）中R1至R3的化合物，其中R1至R3的定义如权利要求书中所述，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物。

  公开号：

  WO2009112565A1
• 作为产物：
  描述：

  肼基甲酸叔丁酯 、 环丙甲醛 以 甲醇 为溶剂， 生成 N'-[1-cyclopropyl-methylidene]-hydrazinecarboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] THIAZOLYL-DIHYDRO-INDAZOLES
  [FR] THIAZOLYLDIHYDROINDAZOLES

  摘要：

  本发明涵盖了一般式（1）中R1至R3的化合物，其中R1至R3的定义如权利要求书中所述，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物。

  公开号：

  WO2009112565A1

文献信息

• [EN] THIAZOLYL-DIHYDRO-INDAZOLES<br/>[FR] THIAZOLYLDIHYDROINDAZOLES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009112565A1

  公开（公告）日：2009-09-17

  The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）中R1至R3的化合物，其中R1至R3的定义如权利要求书中所述，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物。
• Thiazolyl-dihydro-indazoles
  申请人：Boehringer Ingelheim International GmbH

  公开号：US08304556B2

  公开（公告）日：2012-11-06

  The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了通式（1）中定义的化合物，其中R1至R3如权利要求1所定义，适用于治疗由过度或异常细胞增殖特征的疾病，并且其用于制备具有上述特性的药物。
• Thiazolyl-Dihydro-Indazoles
  申请人：McCONNELL Darryl

  公开号：US20120108567A1

  公开（公告）日：2012-05-03

  The present invention encompasses compounds of general formula (1) wherein R 1 to R 3 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物，其中R1到R3的定义如权利要求书中所述，适用于治疗由过度或异常细胞增殖所表征的疾病，并且其用于制备具有上述特性的药物。
• Potent aza-peptide derived inhibitors of HCV NS3 protease
  作者：Srikanth Venkatraman、Wanli Wu、Neng-Yang Shih、F. George Njoroge

  DOI：10.1016/j.bmcl.2009.06.060

  日期：2009.8

  Chronic hepatitis C infection is the primary cause for cirrhosis of the liver and hepatocellular carcinoma leading to liver failure and transplantation. The etiological agent hepatitis C virus produces a single positive strand RNA that is processed further with the help of NS3 serine protease to produce mature virus. Inhibition of this protease can potentially be used to develop drugs for HCV infections. Boceprevir is a ketoamide derived novel inhibitor of HCV NS3 protease that has been progressed to clinical trials and proven to be efficacious in humans. Herein, we report our efforts in identifying an aza-peptide derivative as a potential second generation compound, that lacks electrophilic ketoamide group and are potent in enzyme and replicon assay. (C) 2009 Published by Elsevier Ltd.